Expertise in Alzheimer's Disease

Clinical and Translational Science

Researchers in clinical and translational science at Indiana University School of Medicine test new methods to diagnose, treat and prevent Alzheimer’s disease. Much of this clinical research is led by investigators at the Indiana Alzheimer Disease Center, who work to translate research advances into improved diagnosis and care for people with Alzheimer’s disease.

For example, one of the largest-ever studies on Alzheimer’s disease in people under 65 years of age, the Longitudinal Early-Onset Alzheimer’s Disease Study, is underway at IU School of Medicine to develop clinical and biomarker measures for future clinical and research use for this devastating disease.

Through the Center for Neuroimaging, researchers use advanced brain imaging techniques to detect Alzheimer’s disease before a patient begins to show symptoms. Imaging also helps assess whether potential drugs work by measuring if they clear plaques and tangles (abnormal proteins in the brain that are hallmarks of the disease) or if they slow atrophy or loss of brain volume.

Together, advanced imaging, biomarkers from blood or cerebrospinal fluid, genomics and cognitive testing provide the foundation for an emerging precision medicine of Alzheimer’s disease and related dementias.

National Biobank

National Biobank

The National Centralized Repository for Alzheimer’s Disease provides critical access to more than half a million biological samples from people with Alzheimer’s disease.
Clinical Trials

Clinical Trials

Clinical trials test the safety and effectiveness of new ways to prevent, diagnose and treat Alzheimer's disease. Nearly all medical treatments used today began with clinical trials.
Early-Onset

Early-Onset

The Longitudinal Early-Onset Alzheimer’s Disease Study assesses clinical, cognitive, imaging, biomarker and genetic characteristics of people with early-onset Alzheimer's disease.